Implications for herbal polypharmacy: coumarin-induced hepatotoxicity increased through common herbal phytochemicals astragaloside IV and atractylenolide I

References

• Abraham K, Pfister M, Wöhrlin F, Lampen A. 2011. Relative bioavailability of coumarin from cinnamon and cinnamon-containing foods compared to isolated coumarin: a four-way crossover study in human volunteers. Mol Nutr Food Res. 55 (4):644–653.
   PubMed Web of Science ®Google Scholar
• Abraham K, Wohrlin F, Lindtner O, Heinemeyer G, Lampen A. 2010. Toxicology and risk assessment of coumarin: focus on human data. Mol Nutr Food Res. 54(2):228–239.
   PubMed Web of Science ®Google Scholar
• Backman JT, Granfors MT, Neuvonen PJ. 2006. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol. 62(6):451–461.
   PubMed Web of Science ®Google Scholar
• Born SL, Hu JK, Lehman-McKeeman LD. 2000. O-hydroxyphenylacetaldehyde is a hepatotoxic metabolite of coumarin. Drug Metab Dispos. 28(2):218–223.
   PubMed Web of Science ®Google Scholar
• Brewer CT, Chen T. 2017. Hepatotoxicity of herbal supplements mediated by modulation of cytochrome P450. IJMS. 18(11):2353–2381.
   Google Scholar
• Britza SM, Farrington R, Byard RW, Musgrave IF. 2020. Paracetamol (acetaminophen) hepatotoxicity increases in the presence of an added herbal compound. Legal Med. 47:101740.
   PubMed Web of Science ®Google Scholar
• Bunchorntavakul C, Reddy KR. 2013. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 37(1):3–17.
   PubMed Web of Science ®Google Scholar
• Byard RW. 2010. A review of the potential forensic significance of traditional herbal medicines. J Forensic Sci. 55(1):89–92.
   PubMed Web of Science ®Google Scholar
• Byard RW, Musgrave I, Maker G, Bunce M. 2017. What risks do herbal products pose to the Australian community? Med J Aust. 206(2):86–90.
   PubMed Web of Science ®Google Scholar
• [CMA] Complementary Medicines Australia. 2020. Australia’s complementary medicines: industry audit and trends 2020; [accessed 2022 Jan 31]. https://www.cmaustralia.org.au/resources/CMA-industry-presentation-2020.pdf. Published 2020.
   Google Scholar
• Cox D, O’Kennedy R, Thornes RD. 1989. The rarity of liver toxicity in patients treated with coumarin (1,2-benzopyrone). Hum Toxicol. 8(6):501–506.
   PubMedGoogle Scholar
• Du Y, Zhang Q, Chen GG, Wei P, Tu CY. 2005. Pharmacokinetics of Astragaloside IV in rats by liquid chromatography coupled with tandem mass spectrometry. Eur J Drug Metab Pharmacokinet. 30(4):269–273.
   PubMed Web of Science ®Google Scholar
• EFSA. 2008. Scientific opinion of the panel on food additives, flavourings, processing aids and materials in contact with food on a request from the European Commission on Coumarin in flavourings and other food ingredients with flavouring properties. EFSA J. 6(10):793–808.
   Google Scholar
• Egan D, O’Kennedy R, Moran E, Cox D, Prosser E, Thornes RD. 1990. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev. 22(5):503–529.
   PubMed Web of Science ®Google Scholar
• Feng L, Wang L, Jiang X. 2010. Pharmacokinetics, tissue distribution and excretion of coumarin components from Psoralea corylifolia L. in rats. Arch Pharm Res. 33(2):225–230.
   PubMed Web of Science ®Google Scholar
• Fentem JH, Hammond AH, Garle MJ, Fry MJ. 1992. Toxicity of coumarin and various methyl derivatives in cultures of rat hepatocytes and V79 cells. Toxicol In Vitro. 6(1):21–25.
   PubMed Web of Science ®Google Scholar
• Gilbert JD, Musgrave IF, Hoban C, Byard RW. 2014. Lethal hepatocellular necrosis associated with herbal polypharmacy in a patient with chronic hepatitis B infection. Forensic Sci Int. 241:138–140.
   PubMed Web of Science ®Google Scholar
• Gromek K, Drumond N, Simas P. 2015. Pharmacovigilance of herbal medicines. Int J Risk Saf Med. 27(2):55–65.
   PubMedGoogle Scholar
• Iwata N, Kainuma M, Kobayashi D, Kubota T, Sugawara N, Uchida A, Ozono S, Yamamuro Y, Furusyo N, Ueda K, et al. 2016. The relation between hepatotoxicity and the total coumarin intake from traditional Japanese medicines containing cinnamon bark. Front Pharmacol. 7:174.
   PubMed Web of Science ®Google Scholar
• Ji L, Lu D, Cao J, Zheng L, Peng Y, Zheng J. 2015. Psoralen, a mechanism-based inactivator of CYP2B6. Chem Biol Interact. 240:346–352.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hankins DC, Taraday JK. 2000. Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. Drug Metab Dispos. 28(1):28–33.
   PubMed Web of Science ®Google Scholar
• Lacy A, O’Kennedy R. 2004. Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des. 10(30):3797–3811.
   PubMed Web of Science ®Google Scholar
• Lai JN, Tang JL, Wang JD. 2013. Observational studies on evaluating the safety and adverse effects of traditional Chinese medicine. Evid Based Complement Alternat Med. 2013:697893–697899.
   PubMed Web of Science ®Google Scholar
• Laine JE, Auriola S, Pasanen M, Juvonen RO. 2009. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica. 39(1):11–21.
   PubMed Web of Science ®Google Scholar
• Lau C, Mooiman KD, Maas-Bakker RF, Beijnen JH, Schellens JHM, Meijerman I. 2013. Effect of Chinese herbs on CYP3A4 activity and expression in vitro. J Ethnopharmacol. 149(2):543–549.
   PubMed Web of Science ®Google Scholar
• Li C-Q, He L-C, Hu Y-J. 2007. Pharmacokinetics of atractylenolide I from Atractylodes macrocephala Koidz in rats by RP-HPLC. Asian J Pharmacodyn Pharmacokinet. 7(4):283–288.
   Google Scholar
• Lin MH, Chang HT, Tu CY, Chen TJ, Hwang SJ. 2015. Prevalence of polyherbacy in ambulatory visits to traditional Chinese medicine clinics in Taiwan. Int J Environ Res Public Health. 12(8):9639–9657.
   PubMed Web of Science ®Google Scholar
• Li F, Tang R, Chen LB, Zhang KS, Huang XP, Deng CQ. 2017. Effects of Astragalus combined with Angelica on bone marrow hematopoiesis suppression induced by cyclophosphamide in mice. Biol Pharm Bull. 40(5):598–609.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan J, Kugler J. 1997. Coumarin-induced hepatotoxicity. J Clin Oncol. 15(9):3167–3168.
   PubMed Web of Science ®Google Scholar
• Maher RL, Hanlon J, Hajjar ER. 2014. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 13(1):57–65.
   PubMed Web of Science ®Google Scholar
• Miron A, Aprotosoaie AC, Trifan A, Xiao J. 2017. Flavonoids as modulators of metabolic enzymes and drug transporters. Ann N Y Acad Sci. 1398(1):152–167.
   PubMed Web of Science ®Google Scholar
• Monostory K, Hazai E, Vereczkey L. 2004. Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 147(3):331–340.
   PubMed Web of Science ®Google Scholar
• Morel F, Beaune PH, Ratanasavanh D, Flinois JP, Yang CS, Guengerich FP, Guillouzo A. 1990. Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur J Biochem. 191(2):437–444.
   PubMedGoogle Scholar
• Nash E, Sabih A-H, Chetwood J, Wood G, Pandya K, Yip T, Majumdar A, McCaughan GW, Strasser SI, Liu K. 2021. Drug-induced liver injury in Australia, 2009–2020: the increasing proportion of non-paracetamol cases linked with herbal and dietary supplements. Med J Aust. 215(6):261–268.
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Khan I, Bjornsson E, Seeff LB, Serrano J, Hoofnagle JH. 2017. Liver injury from herbal and dietary supplements. Hepatology. 65(1):363–373.
   PubMed Web of Science ®Google Scholar
• Runge D, Köhler C, Kostrubsky VE, Jäger D, Lehmann T, Runge DM, May U, Stolz DB, Strom SC, Fleig WE, et al. 2000. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem Biophys Res Commun. 273(1):333–341.
   PubMed Web of Science ®Google Scholar
• Seeff LB. 2007. Herbal hepatotoxicity. Clin Liver Dis. 11(3):577–596.
   PubMedGoogle Scholar
• Shan W, Zhang Y, Zhu J, Shao Q, Fan X. 2012. Inhibitory effects of astragaloside IV on cytochrome P450 enzymes of rat liver microsomes. Zhongguo Zhong Yao Za Zhi. 37(1):85–88. PMID: 22741468
   PubMedGoogle Scholar
• Shen C, Meng Q, Zhang G, Hu W. 2008. Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures. Br J Pharmacol. 153 (4):784–791.
   PubMed Web of Science ®Google Scholar
• Song J, Meng L, Li S, Qu L, Li X. 2009. A combination of Chinese herbs, Astragalus membranaceus var. mongholicus and Angelica sinensis, improved renal microvascular insufficiency in 5/6 nephrectomized rats. Vasc Pharmacol. 50(5–6):185–193.
   PubMed Web of Science ®Google Scholar
• Song J, Zheng SR, Jin Y, Li J. 2014. Pharmacokinetic interaction of astragaloside IV with atractylenolide I and prim-O-glucosylcimifugin in male Sprague Dawley rats. Planta Med. 80(2–3):187–192.
   PubMed Web of Science ®Google Scholar
• Srinivas NR. 2016. Pharmacokinetic interaction of rifampicin with oral versus intravenous anticancer drugs: challenges, dilemmas and paradoxical effects due to multiple mechanisms. Drugs R D. 16(2):141–148.
   PubMedGoogle Scholar
• Steel A, McIntyre E, Harnett J, Foley H, Adams J, Sibbritt D, Wardle J, Frawley J. 2018. Complementary medicine use in the Australia population: results of a nationally-representative cross-sectional survey. Sci Rep. 8:17325.
   PubMed Web of Science ®Google Scholar
• Stefanachi A, Leonetti F, Pisani L, Catto M, Carotti A. 2018. Coumarin: a natural, privileged, and versatile scaffold for bioactive compounds. Molecules. 23(2):250.
   PubMed Web of Science ®Google Scholar
• Stickel F, Shouval D. 2015. Hepatotoxicity of herbal and dietary supplements: an update. Arch Toxicol. 89(6):851–865.
   PubMed Web of Science ®Google Scholar
• Stournaras E, Tziomalos K. 2015. Herbal medicine-related hepatotoxicity. World J Hepatol. 7(19):2189–2193.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Fujii W, Hori H, Kitagawa Y, Ozaki K. 2016. Relationship between coumarin-induced hepatocellular toxicity and mitochondrial function in rats. Food Chem Toxicol. 90:1–9.
   PubMed Web of Science ®Google Scholar
• TGA. 2020. Overview of the regulation of listed medicines and registered complementary medicines. Australian Regulatory Guidelines; [accessed 2021 Jun 19]. https://www.tga.gov.au/sites/default/files/overview_of_the_regulation_of_listed_medicines_and_registered_complementary_medicines_0.pdf.
   Google Scholar
• Tinel M, Belghiti J, Descatoire V, Amouyal G, Letteron P, Geneve J, Larrey D, Pessayre D. 1987. Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives. Biochem Pharmacol. 36(6):951–955.
   PubMed Web of Science ®Google Scholar
• Vassallo JD, Hicks SM, Daston GP, Lehman-McKeeman LD. 2004. Metabolic detoxification determines species differences in coumarin-induced hepatotoxicity. Toxicol Sci. 80 (2):249–257.
   PubMed Web of Science ®Google Scholar
• Venugopala KN, Rashmi V, Odhav B. 2013. Review on natural coumarin lead compounds for their pharmacological activity. BioMed Res Int. 2013:1–14. https://dx.doi.org/10.1155/2013/963248.
   Web of Science ®Google Scholar
• Votova K, Blais R, Penning MJ, Maclure MK. 2013. Polypharmacy meets polyherbacy: pharmaceutical, over-the-counter, and natural health products use among Canadian adults. Can J Public Health. 104(3):e222–e228.
   PubMed Web of Science ®Google Scholar
• Wanwimolruk S, Prachayasittikul V. 2014. Cytochrome P450 enzyme mediated herbal drug interactions (part 1). Excli J. 13:347–391.
   PubMedGoogle Scholar
• Wardle J, Adams J, Magalhaes RJ, Sibbritt D. 2011. Distribution of complementary and alternative medicine (CAM) providers in rural New South Wales, Australia: a step towards explaining high CAM use in rural health. Aust J Rural Health. 19(4):197–204.
   PubMed Web of Science ®Google Scholar
• Yan H, Sun Y, Zhang Q, Yang M, Wang X, Wang Y, Yu Z, Zhao Y. 2015. Simultaneous determination and pharmacokinetic study of Atractylenolide I, II and III in rat plasma after intragastric administration of Baizhufuling extract and Atractylodis extract by UPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 993–994:86–92.
   PubMed Web of Science ®Google Scholar
• Yu R, Yu B-X, Chen J-F, Lv X-Y, Yan Z-J, Cheng Y, Ma Q. 2016. Anti-tumor effects of Atractylenolide I on bladder cancer cells. J Exp Clin Cancer Res. 35:1–10.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Deng Y, Chen Y, Chuang PY, He JC. 2013. Therapeutic use of traditional Chinese herbal medications for chronic kidney diseases. Kidney Int. 84(6):1108–1118.
   PubMed Web of Science ®Google Scholar
• Zhou M, Hong Y, Lin X, Shen L, Feng Y. 2017. Recent pharmaceutical evidence on the compatibility rationality of traditional Chinese medicine. J Ethnopharmacol. 206:363–375.
   PubMed Web of Science ®Google Scholar